Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

A novel retromer stabilizer as a potential treatment for Parkinson’s disease
Movement Disorders
P14 - Poster Session 14 (11:45 AM-12:45 PM)
5-016

Reducing αS levels in dopaminergic neurons may have neuroprotective potential in Parkinson’s disease (PD). Mutations in the VPS35 gene are a rare cause of familial PD. VPS35 is a key component of the retromer, a heteropentameric complex involved in protein trafficking. VPS35 regulates the trafficking of proteins involved in three αS degradation pathways: macroautophagy (MA), chaperone-mediated autophagy (CMA), and the endosomal-lysosomal system (ELS).

To test the impact of a novel retromer stabilizer, guanidine hydrazone (2a), on levels of vacuolar protein sorting 35 (VPS35) and on α-synuclein (αS) clearance pathways in human neuroblastoma SH-SY5Y cells. 

We overexpressed exogenous mutant A53T αS by transient transfection in SH-SY5Y cells, co-treated this group with 2a (or vehicle) at 20 uM for 2, 3, 4 or 5 days, and analyzed levels of αS, VPS35, and αS degradation pathway markers by western blot and ELISA. We then looked at the effect of selective MA blockage for 1-day with bafilomycin A1 (BfA1) at 50 nM on the impact of 2a on αS levels.

2a increased VPS35 protein levels (~75%) and retromer function, with increased levels of the VPS35 cargo Sortilin. This correlated with a reduction of phospho-Ser129 αS (~ 80%), an important pathological form of αS, in the cytosolic and soluble fractions and oligomeric αS in the soluble fraction (~ 50%). Furthermore, we found a 2a-induced increase in CMA and MA markers, highlighting its effect on boosting the main αS clearance pathways. After blocking MA, there was a ~60% reduction of phospho-Ser129 αS in the A53T αS-transfected group treated with 2a. Thus, 2a can decrease aS levels even when MA is blocked, potentially by compensatory upregulation of CMA and ELS.

These findings link VPS35 to the regulation of multiple aS degradation pathways, and highlight 2a as a promising candidate for neuroprotection in PD.

Authors/Disclosures
Michele Persico, MD (Emory University School of Medicine)
PRESENTER
Dr. Persico has nothing to disclose.
Tracy-Shi Zhang Fang, PhD (BIDMC RESEARCH) Dr. ZHANG has nothing to disclose.
Carly Laura Tucci Miss Tucci has nothing to disclose.
Darynaisha Crawford, Other Miss Crawford has nothing to disclose.
David K. Simon, MD, PhD (Beth Israel Deaconess Medical Center) Dr. Simon has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Bial Biotech. An immediate family member of Dr. Simon has stock in Biogen. The institution of Dr. Simon has received research support from Weston Brain Institute. The institution of Dr. Simon has received research support from NIH. The institution of Dr. Simon has received research support from Neuraly. Dr. Simon has received personal compensation in the range of $5,000-$9,999 for serving as a Steering Committee Member: SPARK clinical study with Biogen. Dr. Simon has received personal compensation in the range of $500-$4,999 for serving as a Steering Committee Member: NILO-PD clinical study with Michael J Fox Foundation.
Simona Eleuteri, PhD (BIMDC/ Harvard Medical School) Dr. Eleuteri has nothing to disclose.